Abstract
The aim of this work is to review tacrine analogues from the last three years, which were not included in the latest review work, donepezil and galantamine hybrids from 2015 and rivastigmine derivatives from 2014. In this account, we summarize the efforts toward the development and characterization of non-toxic inhibitors of cholinesterases based on mentioned drugs with various interesting additional properties such as antioxidant, decreasing β-amyloid plaque aggregation, nitric oxide production, pro-inflammatory cytokines release, monoamine oxidase-B activity, cytotoxicity and oxidative stress in vitro and in animal model that classify these hybrids as potential multifunctional therapeutic agents for Alzheimer’s disease. Moreover, herein, we have described the cholinergic hypothesis, mechanisms of neurodegeneration and current pharmacotherapy of Alzheimer’s disease based on the restoration of cholinergic function through blocking enzymes that break down acetylcholine.
Keywords: Tacrine, donepezil, galantamine, rivastigmine, multifunctional cholinesterase inhibitors, alzheimer's disease.
Graphical Abstract
Current Neuropharmacology
Title:Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors
Volume: 19 Issue: 8
Author(s): Maja Przybyłowska, Krystyna Dzierzbicka, Szymon Kowalski, Klaudia Chmielewska and Iwona Inkielewicz-Stepniak*
Affiliation:
- Department of Pharmaceutical Pathophysiology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk,Poland
Keywords: Tacrine, donepezil, galantamine, rivastigmine, multifunctional cholinesterase inhibitors, alzheimer's disease.
Abstract: The aim of this work is to review tacrine analogues from the last three years, which were not included in the latest review work, donepezil and galantamine hybrids from 2015 and rivastigmine derivatives from 2014. In this account, we summarize the efforts toward the development and characterization of non-toxic inhibitors of cholinesterases based on mentioned drugs with various interesting additional properties such as antioxidant, decreasing β-amyloid plaque aggregation, nitric oxide production, pro-inflammatory cytokines release, monoamine oxidase-B activity, cytotoxicity and oxidative stress in vitro and in animal model that classify these hybrids as potential multifunctional therapeutic agents for Alzheimer’s disease. Moreover, herein, we have described the cholinergic hypothesis, mechanisms of neurodegeneration and current pharmacotherapy of Alzheimer’s disease based on the restoration of cholinergic function through blocking enzymes that break down acetylcholine.
Export Options
About this article
Cite this article as:
Przybyłowska Maja , Dzierzbicka Krystyna , Kowalski Szymon , Chmielewska Klaudia and Inkielewicz-Stepniak Iwona *, Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors, Current Neuropharmacology 2021; 19 (8) . https://dx.doi.org/10.2174/1570159X19666201218103434
DOI https://dx.doi.org/10.2174/1570159X19666201218103434 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer
Current Medicinal Chemistry A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure
Current Vascular Pharmacology Inhibition of MHC II Gene Transcription by Nitric Oxide and Antioxidants
Current Pharmaceutical Design Rediscovering the Antibiotics of the Hive
Recent Patents on Anti-Infective Drug Discovery A Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab) in the Therapy of Moderate-to-Severe Allergic Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Modulation of ColE1-Like Plasmid Replication for Recombinant Gene Expression
Recent Patents on DNA & Gene Sequences Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of β Amyloid-Induced Astrogliosis <i>In Vitro</i>
CNS & Neurological Disorders - Drug Targets Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design The Normal and Pathologic Roles of the Alzheimer's β-secretase, BACE1
Current Alzheimer Research EDITORIAL (Natural Products for Treatment of Alzheimer's Disease and Related Diseases: Understanding their Mechanism of Action)
Current Neuropharmacology Multiple Sclerosis: Pathogenesis and Treatment
Current Neuropharmacology Consequences of Alcohol Consumption on Neurotransmitters -An Overview
Current Neurovascular Research Non-pharmacological Strategies Against Systemic Inflammation: Molecular Basis and Clinical Evidence
Current Pharmaceutical Design Vasoconstrictor Therapy for Hepatorenal Syndrome in Liver Cirrhosis
Current Pharmaceutical Design The Structure and Main Functions of Aminopeptidase N
Current Medicinal Chemistry Immune Therapy for Infectious Diseases at the Dawn of the 21st Century: the Past, Present and Future Role of Antibody Therapy, Therapeutic Vaccination and Biological Response Modifiers
Current Pharmaceutical Design Fight Against H1N1 Influenza A Virus: Recent Insights Towards the Development of Druggable Compounds
Current Medicinal Chemistry Vatairea Macrocarpa Lectin Induces Paw Edema With Leukocyte Infiltration.
Protein & Peptide Letters The Metabolism of Diclofenac - Enzymology and Toxicology Perspectives
Current Drug Metabolism Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies
Current Clinical Pharmacology